Blow To Genmab As It Is Set To Lose Darzalex Royalties Sooner Than Hoped
As Arbitration Disappoints
The Danish firm will stop receiving royalties on Darzalex after 2030 having has lost on two issues heard at an arbitration tribunal, in a significant blow to its finances.
